
Naltrexone (Low-Dose Naltrexone)
At its labeled doses, naltrexone modestly helps people with alcohol use disorder drink less and, as a monthly injection after detox, helps people with opioid use disorder stay opioid-free. Low-dose naltrexone is an off-label use: the two largest fibromyalgia trials found no benefit over placebo, and evidence for Crohn's disease, multiple sclerosis, long COVID and depression is small, low certainty or negative.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with alcohol use disorder, or with opioid use disorder who have completed detox, whose prescriber recommends naltrexone as part of a treatment program
Common dosing range
Your prescriber sets the dose. Labeled doses: 50 mg tablets once daily (for opioid blockade, starting at 25 mg), or Vivitrol 380 mg injected every 4 weeks. Low-dose use (1 to 6 mg a day) is off-label
When to expect effects
Opioid blocking starts with the first effective dose; Vivitrol blocks opioids for about 28 days per injection. Drinking outcomes were measured over 12 weeks to 6 months
Watch out for
You must be opioid-free for at least 7 to 10 days before starting, or severe withdrawal can occur. After stopping, missing a dose or near the end of a Vivitrol month, a previously tolerated opioid dose can be fatal. Contraindicated with opioid pain medicines. The current labels carry no boxed warning, but warn about liver injury, depression and suicidal thoughts, and (Vivitrol) severe injection-site reactions
What is it
Naltrexone is a prescription opioid blocker (opioid antagonist). It comes as 50 mg naltrexone hydrochloride tablets, approved for alcohol dependence and to block the effects of opioids, and as Vivitrol, a monthly 380 mg injection into the buttock muscle given by a healthcare provider, approved for alcohol dependence in people who can stop drinking before starting and to prevent relapse to opioid dependence after detox. Both labels say it should be used as part of a broader treatment plan for addiction, and the Vivitrol label specifies a program that includes psychosocial support. Naltrexone is also one of the two ingredients in Contrave, a weight-management tablet with bupropion, which this page does not cover. "Low-dose naltrexone" (LDN) means taking roughly 1 to 6 mg a day, a small fraction of the labeled 50 mg dose, for conditions such as fibromyalgia, Crohn's disease or multiple sclerosis. That is an off-label use: no FDA-approved naltrexone product comes in these strengths or is approved for these conditions.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
alcohol use disorder (oral tablets) Good Evidence | Modest; 1 in 12 people treated avoided a return to heavy drinking | Adults with alcohol use disorder who have stopped or are trying to stop drinking, with counseling or medical follow-up | Trials of 12 weeks or longer |
alcohol use disorder (Vivitrol injection) Good Evidence | Moderate; 25% fewer heavy drinking days with 380 mg | Adults who can stop drinking before the first injection, as the label requires | Measured over 6 months |
preventing relapse in opioid use disorder (Vivitrol injection) Good Evidence | Large versus placebo; similar to buprenorphine-naloxone once started | Adults who have completed detox and can stay opioid-free for 7 to 10 days before the first injection | Measured over 24 weeks |
fibromyalgia (low-dose naltrexone, off-label) Good Evidence | None significant in the two largest parallel trials | Not established | Measured at 12 weeks to 12 months |
active Crohn's disease (low-dose naltrexone, off-label) Limited Evidence | Uncertain; better response rates but no significant difference in remission in one small trial | Adults with active Crohn's disease in a specialist's care | Measured at 8 to 12 weeks |
quality of life in multiple sclerosis (low-dose naltrexone, off-label) Limited Evidence | Inconsistent; small improvements in one trial, none in another | Adults with MS, alongside disease-modifying treatment | Measured over 8 to 17 weeks |
depression, added to an antidepressant (low-dose naltrexone, off-label) Limited Evidence | None in the larger trial | Not established | Measured at 3 to 12 weeks |
long COVID (low-dose naltrexone, off-label) Mixed Evidence | Unknown; improvements in uncontrolled studies only | Not established | Not established |
alcohol use disorder (oral tablets)
- Effect
- Modest; 1 in 12 people treated avoided a return to heavy drinking
- Best fit
- Adults with alcohol use disorder who have stopped or are trying to stop drinking, with counseling or medical follow-up
- Time
- Trials of 12 weeks or longer
alcohol use disorder (Vivitrol injection)
- Effect
- Moderate; 25% fewer heavy drinking days with 380 mg
- Best fit
- Adults who can stop drinking before the first injection, as the label requires
- Time
- Measured over 6 months
preventing relapse in opioid use disorder (Vivitrol injection)
- Effect
- Large versus placebo; similar to buprenorphine-naloxone once started
- Best fit
- Adults who have completed detox and can stay opioid-free for 7 to 10 days before the first injection
- Time
- Measured over 24 weeks
fibromyalgia (low-dose naltrexone, off-label)
- Effect
- None significant in the two largest parallel trials
- Best fit
- Not established
- Time
- Measured at 12 weeks to 12 months
active Crohn's disease (low-dose naltrexone, off-label)
- Effect
- Uncertain; better response rates but no significant difference in remission in one small trial
- Best fit
- Adults with active Crohn's disease in a specialist's care
- Time
- Measured at 8 to 12 weeks
quality of life in multiple sclerosis (low-dose naltrexone, off-label)
- Effect
- Inconsistent; small improvements in one trial, none in another
- Best fit
- Adults with MS, alongside disease-modifying treatment
- Time
- Measured over 8 to 17 weeks
depression, added to an antidepressant (low-dose naltrexone, off-label)
- Effect
- None in the larger trial
- Best fit
- Not established
- Time
- Measured at 3 to 12 weeks
long COVID (low-dose naltrexone, off-label)
- Effect
- Unknown; improvements in uncontrolled studies only
- Best fit
- Not established
- Time
- Not established
Evidence for 8 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
alcohol use disorder (oral tablets)
Disease adjunctA 2014 meta-analysis of 122 trials in adults with alcohol use disorder, including 53 trials of naltrexone (9,140 participants), found that oral naltrexone 50 mg a day lowered the return to heavy drinking (1 extra person avoided heavy drinking for every 12 treated) and the return to any drinking (1 in 20, with a wide confidence interval). It did about as well as acamprosate when they were compared directly. In the COMBINE trial of 1,383 recently abstinent US adults, naltrexone 100 mg a day with medical management for 16 weeks increased days abstinent (80.6% vs 75.1% with placebo) and lowered the risk of a heavy drinking day (hazard ratio 0.72); differences were no longer significant a year after treatment.
Bottom line: Naltrexone tablets modestly reduce heavy drinking when added to support.
alcohol use disorder (Vivitrol injection)
Disease adjunctIn a 6-month double-blind trial at 24 US sites, 624 actively drinking alcohol-dependent adults received monthly injections of 380 mg or 190 mg long-acting naltrexone or placebo, plus low-intensity counseling. The 380 mg dose cut the rate of heavy drinking days by 25% compared with placebo; the 190 mg dose by 17%, which was not statistically significant. Effects were larger in men and in people who had stopped drinking before the first injection. The label adds that in the 8% who had stopped drinking the week before the first injection, drinking days, heavy drinking days and abstinence improved, and that these effects were not evident in the 92% who were still drinking at the start.
Bottom line: Monthly Vivitrol reduces heavy drinking, mainly in people who have already stopped before starting.
preventing relapse in opioid use disorder (Vivitrol injection)
Disease adjunctIn a double-blind trial in Russia, 250 adults who had completed detox and been opioid-free for at least 7 days received Vivitrol 380 mg or placebo monthly for 24 weeks with counseling. Confirmed opioid-free weeks were 90.0% versus 35.0% (median), and craving fell. That trial was funded by Alkermes, the maker of Vivitrol. In the US X:BOT trial of 570 adults, starting Vivitrol was harder than starting buprenorphine-naloxone (72% vs 94% got their first dose), so relapse was more common overall (65% vs 57%); among people who did start, relapse rates were similar.
Bottom line: Once started after detox, monthly Vivitrol helps people stay off opioids about as well as buprenorphine.
fibromyalgia (low-dose naltrexone, off-label)
No benefit foundOff-label use at doses far below the labeled 50 mg. In a 12-week double-blind trial in Denmark, 99 women aged 18 to 64 with fibromyalgia took 6 mg a day or placebo: pain fell by 1.3 versus 0.9 points on a 0 to 10 scale, a difference that was not statistically significant. In the 12-month INNOVA trial at one center in Spain, 98 women took 4.5 mg a day or placebo, and pain at 3 months did not improve more than with placebo (minus 0.33 vs minus 0.64 points). A 2025 meta-analysis of 8 studies found no significant difference from placebo. An earlier crossover trial in 31 women reported more pain reduction with 4.5 mg (28.8% vs 18.0%).
Bottom line: Off-label low-dose naltrexone did not relieve fibromyalgia pain better than placebo in the largest trials.
Evidence is mixed
Earlier small crossover trials, including one in 31 women, reported less pain with 4.5 mg, but larger parallel-group trials and a 2025 meta-analysis did not confirm a difference from placebo.
active Crohn's disease (low-dose naltrexone, off-label)
Disease adjunctOff-label use. A 2018 Cochrane review found 2 small placebo-controlled trials (46 participants). In 34 adults given 4.5 mg a day for 12 weeks, remission was 30% versus 18% (not statistically significant), while a 70-point clinical response (83% vs 38%) and endoscopic response (72% vs 25%) were more common. A trial in 12 children mainly tested safety. The review rated the certainty of evidence as low and said there is not enough evidence for firm conclusions.
Bottom line: Too little evidence to know whether off-label low-dose naltrexone helps Crohn's disease.
quality of life in multiple sclerosis (low-dose naltrexone, off-label)
Disease adjunctOff-label use. In a US crossover trial of 80 people with multiple sclerosis (60 completed), 4.5 mg nightly for 8 weeks improved several mental health quality of life scores, but dropouts and data errors reduced the trial's power. In a 17-week trial at two universities with 96 people with relapsing-remitting or secondary progressive MS, quality of life measures did not differ from placebo. Neither trial measured relapses or disability progression as a main outcome.
Bottom line: Two small trials disagree; off-label low-dose naltrexone is unproven for MS.
depression, added to an antidepressant (low-dose naltrexone, off-label)
No benefit foundOff-label use. In a 2026 double-blind trial, 37 people with moderate major depression already taking an antidepressant received up to 4.5 mg a day or placebo for 12 weeks. Depression scores fell by 10.5 versus 9.8 points, with no difference between groups, and an inflammation marker (hsCRP) did not change. A 2017 pilot trial of 12 people taking dopamine-acting antidepressant regimens found better scores on some scales with 1 mg twice daily for 3 weeks, but not on its main measure.
Bottom line: Off-label low-dose naltrexone did not ease depression in the larger of two small trials.
Evidence is mixed
A 12-person pilot trial reported improvement on some depression scales but not on its main measure.
long COVID (low-dose naltrexone, off-label)
Disease adjunctOff-label use. A 2026 systematic review searched through May 2026 and found no randomized controlled trials of low-dose naltrexone in long COVID. Four small before-and-after studies (155 people in the USA and Ireland, 1 to 6 mg a day) reported less fatigue, brain fog and pain, but without a placebo group these changes cannot be separated from natural recovery or expectation, and the authors rated the certainty of evidence as low.
Bottom line: No randomized trial yet shows whether off-label low-dose naltrexone helps long COVID.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose: 50 mg tablets daily or a 380 mg injection monthly after being opioid-free; low-dose use is off-label.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Risk of fatal opioid overdose: after naltrexone is stopped, a dose is missed or a Vivitrol month ends, opioid tolerance is lower than before and previously tolerated opioid doses can cause fatal overdose. Trying to overcome the blockade with large amounts of opioids is especially dangerous. The labels advise discussing access to an opioid overdose reversal medicine such as naloxone or nalmefene.
Precipitated opioid withdrawal: in anyone still dependent on opioids, naltrexone can trigger sudden withdrawal severe enough to need hospital admission and, in some cases, intensive care. The labels recommend at least 7 to 10 days opioid-free (including tramadol) for people previously dependent on short-acting opioids, and people coming off buprenorphine or methadone may be vulnerable for as long as 2 weeks.
Liver injury: cases of hepatitis and clinically significant liver dysfunction have been reported, the labels say patients should be warned of the risk and seek medical attention for symptoms of acute hepatitis, and they say to stop it if signs of acute hepatitis appear. The tablet label notes that placebo-controlled studies of up to 300 mg a day caused liver cell injury in a substantial proportion of people.
Depression, suicide attempts and suicidal thoughts have been reported in people treated with naltrexone for opioid dependence; the tablet label says no causal relationship has been shown, and the Vivitrol label says people treated for alcohol or opioid dependence should be monitored for depression or suicidal thinking.
Vivitrol only: severe injection-site reactions (hard lumps, abscess, tissue death needing surgery), eosinophilic pneumonia (shortness of breath and low oxygen that does not respond to antibiotics) and allergic reactions including anaphylaxis.
Who should avoid it
- People taking opioid pain medicines, people currently dependent on opioids (including those on methadone or buprenorphine), and people in acute opioid withdrawal (contraindicated)
- Anyone who failed a naloxone challenge test or has a positive urine screen for opioids (contraindicated)
- People with a previous allergic reaction to naltrexone or, for Vivitrol, to its microspheres (PLG), carboxymethylcellulose or diluent (contraindicated)
- People with moderate to severe kidney impairment or severe liver impairment need extra care rather than avoidance (this is not a contraindication): Vivitrol has not been studied in them, and the label recommends caution in moderate to severe kidney impairment
Pregnancy & breastfeeding
Pregnancy: the Vivitrol label says the available data from published case series are not enough to identify a drug-related risk of major birth defects, miscarriage or other harm, and that untreated opioid addiction and alcohol use in pregnancy carry their own serious risks to the baby. In animal studies, oral naltrexone increased early pregnancy loss in rats and rabbits but did not cause malformations. The tablet label says it should be used in pregnancy only if the potential benefit justifies the potential risk. Breastfeeding: the tablet label says it is unknown whether naltrexone passes into human milk and advises caution. The newer Vivitrol label says naltrexone and its main breakdown product pass into human milk, with no data on effects on the baby or on milk supply, and that the benefits of breastfeeding should be weighed against the mother's need for treatment. Anyone pregnant, planning pregnancy or breastfeeding should discuss it with their prescriber.
Interactions
Naltrexone is contraindicated in people taking opioid pain medicines and blocks the effect of opioid-containing cough, cold and antidiarrheal products. Taking opioids while on it can cause withdrawal, and taking large amounts to overcome the block can cause fatal overdose. For emergency pain, the label suggests options such as regional analgesia (numbing a region of the body) or non-opioid pain relievers, and if opioids are needed the dose may be higher and breathing effects deeper and longer. Tell every prescriber and your pharmacist that you take naltrexone.
The tablet label says naltrexone is contraindicated in people currently maintained on methadone or buprenorphine, because it can trigger severe withdrawal. People switching from these medicines may be vulnerable to withdrawal for as long as 2 weeks, so the switch is planned by the prescriber.
The tablet label says the safety and effectiveness of using naltrexone with disulfiram are unknown, and that combining two medicines that can harm the liver is not ordinarily recommended unless the likely benefits outweigh the risks. Your prescriber decides whether the combination is appropriate and how to monitor your liver.
The tablet label reports lethargy and sleepiness after doses of naltrexone taken with the antipsychotic thioridazine. Tell your prescriber if you take it.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
What is low-dose naltrexone, and is it approved?⌄
Low-dose naltrexone (LDN) means taking about 1 to 6 mg a day, far below the labeled 50 mg tablet dose. It is an off-label use: no FDA-approved naltrexone product comes in these strengths or is approved for fibromyalgia, Crohn's disease, MS, long COVID or other conditions it is promoted for. A prescriber may still choose it, but the evidence is limited.
Does low-dose naltrexone work for fibromyalgia?⌄
The best trials say probably not. In two parallel trials of about 100 women each (6 mg and 4.5 mg a day), pain did not improve more than with placebo, and a 2025 meta-analysis found no significant difference. Earlier small crossover studies were more positive. Side effects were about as common as with placebo.
What is the difference between Vivitrol and naltrexone tablets?⌄
Both contain naltrexone. Tablets are 50 mg taken by mouth once a day, approved for alcohol dependence and to block opioids. Vivitrol is a 380 mg injection given by a healthcare provider every 4 weeks, approved for alcohol dependence in people who can stop drinking before starting and to prevent relapse after opioid detox. The monthly injection avoids the need to remember a daily pill.
Can I take opioid pain medicine while on naltrexone?⌄
Naltrexone is contraindicated with opioid pain medicines: it blocks them and can cause withdrawal, and trying to overcome the block with large doses can be fatal. Tell every doctor, dentist and pharmacist you take naltrexone, and carry information about it. Do not stop it on your own before a procedure; your prescriber plans that.
Can I take naltrexone with my supplements?⌄
Our interaction database has no supplement pairs for naltrexone yet, and the tablet label says interaction studies with drugs other than opioids have not been done. Opioid-containing products are the main concern, so check any cough, cold or diarrhea remedy and any herbal product with your pharmacist before using it.
Why is overdose a risk after stopping naltrexone?⌄
While you take naltrexone, your body loses some of its tolerance to opioids. When it wears off, after you stop, miss a dose or reach the end of a Vivitrol month, an opioid dose you used to tolerate can stop your breathing. The labels advise talking with your provider about having an overdose reversal medicine such as naloxone available.
References by claim
alcohol use disorder (oral tablets)
alcohol use disorder (Vivitrol injection)
Garbutt et al., 2005 · PubMed (2005) link
preventing relapse in opioid use disorder (Vivitrol injection)
fibromyalgia (low-dose naltrexone, off-label)
active Crohn's disease (low-dose naltrexone, off-label)
Parker et al., 2018 · PMC (2018) link
quality of life in multiple sclerosis (low-dose naltrexone, off-label)
long COVID (low-dose naltrexone, off-label)
Byambasuren et al., 2026 · PMC (2026) link
depression, added to an antidepressant (low-dose naltrexone, off-label)
Track Naltrexone (Low-Dose Naltrexone) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
